Education
About Us
Working with TipRanks
Follow Us
MiMedx Group (MDXG)
NASDAQ:MDXG
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.05Last Year’s EPS
0.06Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 4.87%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, a solid cash position, and successful international expansion. However, challenges related to Medicare reimbursement and potential market disruption due to new LCD implementations were noted. Legal and regulatory issues also present ongoing challenges.Company Guidance
During the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call, the company reported a full-year revenue growth of 9%, with Q4 net sales increasing by 7% to $93 million. Gross profit margin for the quarter was 82%, and adjusted EBITDA was $20 million, representing 21% of sales. For the full year, adjusted EBITDA was $76 million, or 22% of sales, marking an $18 million increase from the previous year. The company ended the year with $104 million in cash, an increase of $16 million during the quarter. MiMedx also highlighted its strategic priorities, including the market release of HELIOGEN, expanding its footprint in the surgical market, and enhancing customer intimacy. Looking ahead, MiMedx anticipates 2025 to be another successful year, with expected net sales growth in the high single digits and an adjusted EBITDA margin above 20%, assuming the implementation of new Medicare reimbursement policies in April.Solid Year-Over-Year Revenue Growth
MiMedx reported a 9% increase in full-year revenue with a strong 7% growth in Q4, reaching $93 million.
High Gross Profit Margin
The company maintained a high gross profit margin of 82% in Q4 2024.
Strong Cash Position
MiMedx ended the year with $104 million in cash, an increase of $16 million during the quarter.
International Market Success
Sales in Japan for the EpiFix product nearly tripled in 2024.
Product Innovation and Market Acceptance
HELIOGEN, a new product in the surgical market, began gaining traction, with AMNIOEFFECT growing close to 20% year-over-year.
---
MDXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MDXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $8.01 | $8.14 | +1.62% |
| Oct 30, 2024 | $5.69 | $6.85 | +20.39% |
| Jul 30, 2024 | $7.59 | $7.45 | -1.84% |
| Apr 30, 2024 | $6.16 | $7.31 | +18.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MiMedx Group (MDXG) report earnings?
MiMedx Group (MDXG) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is MiMedx Group (MDXG) earnings time?
MiMedx Group (MDXG) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDXG EPS forecast?
MDXG EPS forecast for the fiscal quarter 2025 (Q1) is 0.05.
---